Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

Wedbush analyst David Nierengarten has reiterated an 'Outperform' rating on Telix Pharmaceuticals (NASDAQ: TLX) and maintains a price target of $22 for the stock. This endorsement reflects the analyst's positive outlook on the company's performance.